Organogenesis Holdings Inc (ORGO) concluded trading on Thursday at a closing price of $4.53, with 3.87 million shares of worth about $17.55 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 45.66% during that period and on April 24, 2025 the price saw a gain of about 1.80%. Currently the company’s common shares owned by public are about 125.73M shares, out of which, 64.38M shares are available for trading.
Stock saw a price change of 6.59% in past 5 days and over the past one month there was a price change of -13.22%. Year-to-date (YTD), ORGO shares are showing a performance of 41.56% which increased to 52.53% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.16 but also hit the highest price of $6.71 during that period. The average intraday trading volume for Organogenesis Holdings Inc shares is 2.01 million. The stock is currently trading 7.37% above its 20-day simple moving average (SMA20), while that difference is up 2.29% for SMA50 and it goes to 30.62% higher than SMA200.
Organogenesis Holdings Inc (NASDAQ: ORGO) currently have 125.73M outstanding shares and institutions hold larger chunk of about 47.81% of that.
The stock has a current market capitalization of $574.53M and its 3Y-monthly beta is at 1.83. PE ratio of stock for trailing 12 months is 808.93, while it has posted earnings per share of $0.01 in the same period. It has Quick Ratio of 3.35 while making debt-to-equity ratio of 0.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ORGO, volatility over the week remained 5.27% while standing at 8.11% over the month.
Stock’s fiscal year EPS is expected to rise by 625.00% while it is estimated to increase by 255.56% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Lake Street on June 28, 2024 offering a Buy rating for the stock and assigned a target price of $5 to it. Coverage by Cantor Fitzgerald stated Organogenesis Holdings Inc (ORGO) stock as an Overweight in their note to investors on February 07, 2024, suggesting a price target of $5 for the stock. On June 15, 2023, Morgan Stanley Initiated their recommendations, while on May 24, 2023, BTIG Research Upgrade their ratings for the stock with a price target of $10. Stock get a Neutral rating from BTIG Research on November 10, 2022.
